Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 2/2016

01-02-2016 | Pediatric Rheumatology (S Ozen, Section Editor)

Current Research in Outcome Measures for Pediatric Rheumatic and Autoinflammatory Diseases

Authors: Erkan Demirkaya, Alessandro Consolaro, Hafize Emine Sonmez, Gabriella Giancane, Dogan Simsek, Angelo Ravelli

Published in: Current Rheumatology Reports | Issue 2/2016

Login to get access

Abstract

A rational management of children and adolescents with rheumatic and autoinflammatory diseases requires the regular assessment of the level of disease activity and of child health and well-being through the use of well-validated outcome measures. Ideally, such instruments should be simple and feasible and easily applicable in standard clinical practice. In recent years, a number of novel outcome measures have been developed and validated for use in pediatric patients with rheumatic and autoinflammatory illnesses. Furthermore, there has been an increased focus on the appraisal of child and parent perception of the disease impact. The new tools have markedly enlarged the spectrum of disorders and health domains that can be assessed in a standardized way. This progress will help to enhance the reliability of research studies and clinical trials. The aim of the present review is to provide an update of the recent advances in this field of research.
Literature
1.
Petty RE, Cassidy JT. Chronic arthritis in childhood. In: Cassidy JT, Petty RE, Laxer RM, Lindsley CB, editors. Textbook of pediatric rheumatology. 6th ed. Philadelphia: Elsevier Saunders; 2011. p. 211–35.CrossRef
2.
Ravelli A. Handbook of juvenile idiopathic arthritis. Adis. 2015;1–124.
3.
Federici S, Gattorno M. A practical approach to the diagnosis of autoinflammatory diseases in childhood. Best Pract Res Clin Rheumatol. 2014;28:263–76.CrossRefPubMed
4.
Brunner HI, Ravelli A. Developing outcome measures for paediatric rheumatic diseases. Best Pract Res Clin Rheumatol. 2009;23:609–24.CrossRefPubMed
5.••
Luca NJ, Feldman BM. Health outcomes of pediatric rheumatic diseases. Best Pract Res Clin Rheumatol. 2014;28:331–50. A thorough review of outcome measures for pediatric rheumatic diseases, which includes the discussion of potential avenues for future research.CrossRefPubMed
6.•
Filocamo G, Consolaro A, Ferrari C, Ravelli A. Introducing new tools for assessment of parent- and child-reported outcomes in paediatric rheumatology practice: a work in progress. Clin Exp Rheumatol. 2013;31:964–8. This paper presents the rationale that underlie the development of multidimensional questionnaires for pediatric rheumatic diseases and highlights the advantages provided by the regular use of these tools in daily practice.PubMed
7.
Filocamo G, Consolaro A, Solari N, Palmisani E, Dalprà S, Suffia C, et al. Recent advances in quantitative assessment of juvenile idiopathic arthritis. Ann Paediatr Rheum. 2012;1:84–96.CrossRef
8.
Duffy CM. Measurement of health status, functional status, and quality of life in children with juvenile idiopathic arthritis: clinical science for the pediatrician. Pediatr Clin North Am. 2005;52:359–72.CrossRefPubMed
9.
Brunner HI, Giannini EH. Health-related quality of life in children with rheumatic diseases. Curr Opin Rheumatol. 2003;15:602–12.CrossRefPubMed
10.
Feldman BM, Grundland B, Mccullough L, Wright V. Distinction of quality of life, health related quality of life, and health status in children referred for rheumatologic care. J Rheumatol. 2000;27:226–33.PubMed
11.
Berard R, Laxer RM. Improving the quality of care in children with juvenile idiopathic arthritis: a step in the right direction. J Rheumatol. 2011;38:789–90.CrossRefPubMed
12.
Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40:1202–9.CrossRefPubMed
13.
Viola S, Felici E, Magni-Manzoni S, Pistorio A, Buoncompagni A, Ruperto N, et al. Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis. Arthritis Rheum. 2005;52:2092–102.CrossRefPubMed
14.
Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61:658–66.CrossRefPubMed
15.
Eb N, Zak M, Aalto K, Berntson L, Fasth A, Herlin T, et al. Validity and predictive ability of the juvenile arthritis disease activity score based on CRP versus ESR in a Nordic population-based setting. Ann Rheum Dis. 2012;71:1122–7.CrossRef
16.••
Consolaro A, Bracciolini G, Ruperto N, Pistorio A, Magni-Manzoni S, Malattia C, et al. Remission, minimal disease activity and acceptable symptom state in juvenile idiopathic arthritis. Arthritis Rheum. 2012;64:2366–74. This article illustrates the process that led to the development and preliminary validation of the JADAS cutoffs corresponding to the main disease activity states in JIA.CrossRefPubMed
17.•
Consolaro A, Ruperto N, Bracciolini G, et al. Defining criteria for high disease activity in juvenile idiopathic arthritis based on the Juvenile Arthritis Disease Activity Score. Ann Rheum Dis. 2014;73:1380–3. This article illustrates the same as above for the state of high disease activity.CrossRefPubMed
18.
Consolaro A, Calandra S, Robbiano C, Ravelli A. Treating juvenile idiopathic arthritis according to JADAS-based targets. Ann Paediatr Rheum. 2014;3:4–10.
19.•
Bulatovic CM, De Vries LD, Vastert SJ, Heijstek MW, Wulffraat NM. Interpretation of the Juvenile Arthritis Disease Activity Score: responsiveness, clinically important differences and levels of disease activity in prospective cohorts of patients with juvenile idiopathic arthritis. Rheumatology. 2014;53:307–12. An analysis of the metrologic properties of the JADAS, which includes the definition of its cutoffs for disease activity states.CrossRef
20.
Backström M, Tynjälä P, Ylijoki H, Aalto K, Kärki J, Pohjankoski H, et al. Finding specific 10-joint Juvenile Arthritis Disease Activity Score (JADAS10) and clinical JADAS10 cut-off values for disease activity levels in non-systemic juvenile idiopathic arthritis: a Finnish multicentre study. Rheumatology (Oxford), in press.
21.•
Consolaro A, Negro G, Lanni S, Solari N, Martini A, Ravelli A. Toward a treat-to-target approach in the management of juvenile idiopathic arthritis. Clin Exp Rheumatol. 2012;30 Suppl 73:S157–62. This paper highlights the potential advantages of the application of the treat-to-target strategy in the management of JIA.PubMed
22.
Mcerlane F, Beresford MW, Baildam EM, Chieng SE, Davidson JE, Foster HE, et al. Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis. Ann Rheum Dis. 2013;72:1983–8.CrossRefPubMedPubMedCentral
23.•
Consolaro A, Negro G, Gallo MC, Bracciolini G, Ferrari C, Schiappapietra B, et al. Defining criteria for disease activity states in non-systemic juvenile idiopathic arthritis based on a three-variable juvenile arthritis disease activity score. Arthritis Care Res (Hoboken). 2014;66:1703–9. This study provides a definition of the criteria for JIA activity states based on the 3-item (clinical) JADAS.CrossRef
24.
Horneff G, Becker I. Definition of improvement in juvenile idiopathic arthritis using the Juvenile Arthritis Disease Activity Score. Rheumatology (Oxford). 2014;53:1229–34.CrossRef
25.
Consolaro A, Ravelli A. Defining criteria for disease activity states in juvenile idiopathic arthritis. What are the optimal JADAS cut-offs? Rheumatology (Oxford), in press.
26.
Filocamo G, Consolaro A, Schiappapietra B, Dalpra S, Lattanzi B, Magni-Manzoni S, et al. A new approach to clinical care of juvenile idiopathic arthritis: the Juvenile Arthritis Multidimensional Assessment Report. J Rheumatol. 2011;38:938–53.CrossRefPubMed
27.
Consolaro A, Ruperto N, Pistorio A, Lattanzi B, Solari N, Galasso R, et al. Development and initial validation of composite parent- and child-centered disease assessment indices for juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011;63:1262–70.CrossRef
28.
Filocamo G, Consolaro A, Schiappapietra B, Ruperto N, Pistorio N, Solari N, et al. A parent and child acceptable symptom state in juvenile idiopathic arthritis. J Rheumatol. 2012;39:856–63.CrossRefPubMed
29.
Pincus T, Mandelin AM, Swearingen CJ. Flowsheets that include MDHAQ physical function, pain, global, and RAPID3 scores, laboratory tests, and medications to monitor patients with all rheumatic diseases: an electronic database for an electronic medical record. Rheum Dis Clin North Am. 2009;35:829-xi.CrossRef
30.
Consolaro A, Ruperto N, Filocamo G, Lanni S, Bracciolini G, Garrone M, et al. Seeking insights into the EPidemiology, treatment and outcome of childhood arthritis through a multinational collaborative effort: introduction of the EPOCA study. Pediatr Rheumatol Online J. 2012;10:39.CrossRefPubMedPubMedCentral
31.•
Weiss PF, Colbert RA, Xiao R, Feudtner C, Beukelman T, DeWitt EM, et al. Development and retrospective validation of the juvenile spondyloarthritis disease activity index. Arthritis Care Res (Hoboken). 2014;66:1775–82. This paper describes the project that led to the development and validation of the first disease activity measure for juvenile spondyloarthropathies.CrossRef
32.
Lam GKW, Petri M. Assessment in systemic lupus erythematosus. Clin Exp Rheumatol. 2005;23 Suppl 39:S120–32.PubMed
33.
Isenberg D, Ramsey-Goldman R. Assessing patients with lupus: towards a drug responder index. Rheumatology. 1999;38:1045–9.CrossRefPubMed
34.
Gladman DD, Ginzler E, Goldsmith CH, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39:363–9.CrossRefPubMed
35.
Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C, et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index in patients with systemic lupus erythematosus. Arthritis Rheum. 1997;40:809–13.CrossRefPubMed
36.
Gutiérrez-Suárez R, Ruperto N, Gastaldi R, Pistorio A, Felici E, Burgos-Vargas R, et al. A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. Arthritis Rheum. 2006;54:2989–96.CrossRefPubMed
37.
Moorthy LN, Harrison M, Peterson M, Onel K, Lehman T. Simple Measure of the Impact of Lupus Erythematosus in Youngsters (SMILEY): examination of psychometric properties [abstract]. Arthritis Rheum. 2003;48 Suppl 9:S687.
38.
Moorthy LN, Peterson MG, Baratelli M, Harrison MJ, Onel KB, Chalom EC, et al. Multicenter validation of a new quality of life measure in pediatric lupus. Arthritis Rheum. 2007;15(57):1165–73.CrossRef
39.
Bode RK, Klein-Gitelman MS, Miller ML, Lechman TS, Pachman LM. Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum. 2003;49:7–15.CrossRefPubMed
40.
Rider LG, Giannini EH, Harris-Love M, Joe G, Isenberg D, Pilkington C, et al. International myositis assessment and clinical studies group. Defining clinical improvement in adult and juvenile myositis. J Rheumatol. 2003;30:603–17.PubMed
41.
Miller FW, Rider LG, Chung YL, Cooper R, Danko K, Farewell V, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology. 2001;40:1262–73.CrossRefPubMed
42.
Isenberg DA, Allen E, Farewell V, Ehrenstein MR, Hanna MG, Lundberg IE, et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology. 2004;43:49–54.CrossRefPubMed
43.
Ravelli A, Ruperto N, Trail L, Felici E, Sala E, Martini A. Clinical assessment in juvenile dermatomyositis. Autoimmunity. 2006;39:197–203.CrossRefPubMed
44.
Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet. 2008;371:2201–12.CrossRefPubMed
45.
Wedderburn LR, Rider LG. Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment. Best Pract Res Clin Rheumatol. 2009;23:665–78.CrossRefPubMedPubMedCentral
46.
Kendall FP, McCreary EK, Provance PG. Muscles: testing and function. 4th ed. Baltimore: Williams and Wilkins; 1993.
47.
Hicks J, Wesley R, Koziol D, Smith M, Jain M, Cintas H, et al. Preliminary validation of abbreviated manual muscle testing (MMT) in the assessment of juvenile dermatomyositis (JDM) [abstract]. Arthritis Rheum. 2000;43(Suppl):S195.
48.
Lovell DJ, Lindsley CB, Rennebohm RM, Ballinger SH, Bowyer SL, Giannini EH, et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. Arthritis Rheum. 1999;42:2213–9.CrossRefPubMed
49.
Marafon D, Consolaro A, Ferrari C, Dalprà S, Madeo A, Providenti A, et al. PReS-FINAL-2011: preliminary validation of a new hybrid measure of muscle strength for juvenile dermatomyositis. Pediatr Rheumatol. 2013;11 Suppl 2:24.CrossRef
50.
Ferrari C, Consolaro A, Varnier GC, Rao AP, Lazarevic D, Demirkaya E, et al. Comparison of construct validity of two functional ability measures in children with juvenile dermatomyositis. Ann Rheum Dis. 2012;71 Suppl 3:427.CrossRef
51.
Arkachaisri T, Vilaiyuk S, Li S, O’Neil KM, Pope E, Higgins GC, et al. The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures. J Rheumatol. 2009;36:2819–29.CrossRefPubMedPubMedCentral
52.
Arkachaisri T, Pino S. Localized scleroderma severity index and global assessments: a pilot study of outcome instruments. J Rheumatol. 2008;35:650–7.CrossRefPubMed
53.•
La Torre F, Martini G, Russo R, Katsicas MM, Corona F, Calcagno G, et al. A preliminary disease severity score for juvenile systemic sclerosis. Arthritis Rheum. 2012;64:4143–50. A report of the project aimed to develop a disease activity score for juvenile systemic sclerosis.CrossRefPubMed
54.
Luqmani R, Bacon P, Moots R, Janssen B, Pall A, Emery P, et al. Birmingham vasculitis activity score (BVAS) in systemic necrotizing vasculitis. QJM. 1994;87:671.PubMed
55.
Luqmani R, Exley A, Kitas G, Bacon P. Disease assessment and management of the vasculitides. Baillieres Clin Rheumatol. 1997;11:423.CrossRefPubMed
56.
Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009;68:1827.CrossRefPubMed
57.•
Demirkaya E, Ozen S, Pistorio A, Galasso R, Ravelli A, Hasija R, et al. Performance of Birmingham Vasculitis Activity Score and disease extent index in childhood vasculitides. Clin Exp Rheumatol. 2012;30(1 Suppl 70):S162–8. The first evaluation of the performance of disease activity measures in pediatric vasculitides.PubMed
58.••
Dolezalova P, Price-Kuehne FE, Ozen S, Benseler SM, Cabral DA, Anton J, et al. Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS). Ann Rheum Dis. 2013;72:1628–33. An important international collaborative study that led to devised a disease activity score for pediatric vasculitides that is suitable for use research, clinical trials, and routine practice.CrossRefPubMed
59.
Herlyn K, Hellmich B, Seo P, Merkel P. Patient reported outcome assessment in vasculitis provides important data and a unique perspective. Arthritis Care Res (Hoboken). 2010;62:1639–45.CrossRef
60.•
Fidanci BE, Demirkaya E, Acikel C, Fidanci K, Karaman D, Yildiz D, et al. The invisible part of the iceberg: qualitative aspects of childhood vasculitis. Clin Exp Rheumatol. 2014;32(3 Suppl 82):S122–7. This Turkish study provides evidence-based information on physical, emotional and social aspects for the assessment of children with vasculitis.PubMed
61.
Exley A, Bacon P, Luqmani R, Kitas G, Gordon C, Savage C, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum. 1997;40:371–80.CrossRefPubMed
62.••
Piram M, Kone-Paut I, Lachmann HJ, Frenkel J, Ozen S, Kuemmerle-Deschner J, et al. Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromes. Ann Rheum Dis. 2014;73:2168–73. This paper paper introduces the first disease activity index for autoinflammatory diseases, including FMF, TRAPS, MKD, and CAPS.CrossRefPubMedPubMedCentral
63.
Ozen S, Batu ED. The myths we believed in familial Mediterranean fever: what have we learned in the past years? Semin Immunopathol. 2015;37:363–9.CrossRefPubMed
64.
Ter Haar NM, Oswald M, Jeyaratnam J, Anton J, Barron KS, Brogan PA, et al. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis. 2015;74:1636–44.CrossRefPubMed
65.•
Konukbay DYD, Acikel C, Karaman D, Fidanci BE, Bilginer Y, Polat A, et al. Evaluation of biopsychosocial aspects of patients with juvenile autoinflammatory disease: a qualitative study. Ann Paediatr Rheum. 2014;3:62–71. This Turkish study is aimed to identify the domains that are worth of inclusion in a multidimensional tool for children with autoinflammatory diseases.CrossRef
66.
Konukbay DYD, Acikel C, Sozeri B, Makay B, Ayaz NA, Barut K, et al. Development and validation of juvenile autoinflammatory disease multidimensional assessment report (JAIMAR). Pediatr Rheumatol. 2014;12 Suppl 1:O23.CrossRef
67.••
Ozen S, Demirkaya E, Duzova A, Erdogan O, Erken E, Gul A, et al. FMF50: a score for assessing outcome in familial Mediterranean fever. Ann Rheum Dis. 2014;73:897–901. This study contains the first criteria for the assessment of treatment response in familial Mediterranean fever.CrossRefPubMed
68.
Rigante D, La Torraca I, Avallone L, Pugliese AL, Gaspari S, Stabile A. The pharmacologic basis of treatment with colchicine in children with familial Mediterranean fever. Eur Rev Med Pharmacol Sci. 2006;10:173–8.PubMed
69.
Yesilkaya S, Acikel C, Fidanci BE, Sozeri B, Ayaz NA, Akıncı B, et al. FMF Arthritis Vasculitis and Orphan disease Research in Paediatric Rheumatology (FAVOR): developing of a new scale for assessing the adherence to colchicines treatment in pediatric patients with FMF. Pediatr Rheumatol. 2013;11 Suppl 2:194.CrossRef
70.•
Yesilkaya S, Acikel C, Fidanci BE, Polat A, Sozeri B, Ayaz NA, et al. Development of a medication adherence scale for familial Mediterranean fever (MASIF) in a cohort of Turkish children. Clin Exp Rheumatol. 2015;33(6 Suppl 94):156–62. This article presents a tool for the assessment of adherence to medication prescription in children with familial Mediterranean fever.
71.
Pras E, Livneh A, Balow Jr JE, Pras E, Kastner DL, Pras M, et al. Clinical differences between North African and Iraqi Jews with familial Mediterranean fever. Am J Med Genet. 1998;75:216–9.CrossRefPubMed
72.
Mor A, Shinar Y, Zaks N, Langevitz P, Chetrit A, Shtrasburg S, et al. Evaluation of disease severity in familial Mediterranean fever. Semin Arthritis Rheum. 2005;35:57–64.CrossRefPubMed
73.
Kalkan G, Demirkaya E, Acikel CH, Polat A, Peru H, Karaoglu A, et al. Evaluation of the current disease severity scores in paediatric FMF: is it necessary to develop a new one? Rheumatology (Oxford). 2012;51:743–8.CrossRef
74.
Demirkaya E, Livneh A. Evaluation of the current scoring systems in familial Mediterranean fever. In Gattorno M, editor. Familial Mediterranean fever. Springer; 2015. pp.107–118.
Metadata
Title
Current Research in Outcome Measures for Pediatric Rheumatic and Autoinflammatory Diseases
Authors
Erkan Demirkaya
Alessandro Consolaro
Hafize Emine Sonmez
Gabriella Giancane
Dogan Simsek
Angelo Ravelli
Publication date
01-02-2016
Publisher
Springer US
Published in
Current Rheumatology Reports / Issue 2/2016
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-015-0558-4

Other articles of this Issue 2/2016

Current Rheumatology Reports 2/2016 Go to the issue

Spondyloarthritis (MA Khan, Section Editor)

Causality of Chlamydiae in Arthritis and Spondyloarthritis: a Plea for Increased Translational Research

Antiphospholipid Syndrome (S Zuily, Section Editor)

Non-stroke Central Neurologic Manifestations in Antiphospholipid Syndrome

Antiphospholipid Syndrome (S Zuily, Section Editor)

Organ Damage and Quality of Life in Antiphospholipid Syndrome

Scleroderma (J Varga, Section Editor)

Cellular Therapies in Systemic Sclerosis: Recent Progress

Scleroderma (J Varga, Section Editor)

Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits